{"id":420153,"date":"2021-01-25T08:03:45","date_gmt":"2021-01-25T13:03:45","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=420153"},"modified":"2021-01-25T08:03:45","modified_gmt":"2021-01-25T13:03:45","slug":"eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/","title":{"rendered":"Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy\u2122 (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">&#8211;  The Eiger OneCare\u2122 Program Provides Ongoing Patient Support Services<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">PALO ALTO, Calif.<\/span>, <span class=\"xn-chron\">Jan. 25, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced the commercial launch and availability of Zokinvy\u2122\u00a0(lonafarnib) in <span class=\"xn-location\">the United States<\/span>. \u00a0Zokinvy was approved by the U.S. Food and Drug Administration (FDA) in <span class=\"xn-chron\">November 2020<\/span> to reduce the risk of death in patients with Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and for the treatment of processing-deficient progeroid laminopathies. <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg\" title=\"Eiger BioPharmaceuticals (PRNewsFoto\/Eiger BioPharmaceuticals, Inc.)\" alt=\"Eiger BioPharmaceuticals (PRNewsFoto\/Eiger BioPharmaceuticals, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>&#8220;Eiger sought regulatory approval of Zokinvy to ensure continued access to the only drug proven to reduce the risk of death in patients with Progeria,&#8221; said <span class=\"xn-person\">Eldon Mayer<\/span>, Chief Commercial Officer of Eiger. \u00a0&#8220;To fulfill our commitment to patients, we established Eiger OneCare\u2122. \u00a0This comprehensive program includes personalized support by specialized care managers, reimbursement experts, co-pay assistance for eligible patients\u00a0and other patient support services designed to assist patients seeking access to Zokinvy.&#8221;<\/p>\n<p>Most of the identified Zokinvy-eligible patients in the U.S. have received Zokinvy through Eiger&#8217;s global expanded access program and are now enrolled in Eiger OneCare which will facilitate a smooth transition to Zokinvy commercial supply.\u00a0 <\/p>\n<p>Eiger OneCare will be available Monday through Friday from <span class=\"xn-chron\">9 AM to 5 PM Eastern Time<\/span> at 1-833-MYEIGER (1-833-693-4437).<\/p>\n<p>For more information, visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045695-1&amp;h=1613235186&amp;u=http%3A%2F%2Fwww.zokinvy.com%2F&amp;a=www.Zokinvy.com\" rel=\"nofollow noopener noreferrer\">www.Zokinvy.com<\/a>.<\/p>\n<p>For healthcare professionals with questions about Zokinvy, call Eiger&#8217;s Medical Information department at 833-267-0545.<\/p>\n<p>\n        <b>About Zokinvy (lonafarnib)<\/b>\n      <\/p>\n<p>Zokinvy blocks the accumulation of defective, farnesylated proteins which form\u00a0tight\u00a0associations\u00a0with\u00a0the\u00a0nuclear\u00a0envelope,\u00a0leading\u00a0to\u00a0cellular\u00a0instability and the process of premature aging in children and young adults with Progeria and processing-deficient Progeroid Laminopathies.<\/p>\n<p>Eiger licensed exclusive worldwide rights to lonafarnib from Merck, known as MSD outside of <span class=\"xn-location\">the United States<\/span> and Canada.\u00a0 Merck will not receive any milestone payments for the development of lonafarnib for the treatment of Progeria and has waived royalty obligations from Eiger for a specified quantity of lonafarnib.<\/p>\n<p>\n        <b>About<\/b><br \/>\n        <b>\u00a0<\/b><br \/>\n        <b>Progeria and Progeroid Laminopathies<\/b>\n      <\/p>\n<p>Progeria, also known as Hutchinson\u2013Gilford Progeria Syndrome\u00a0(HGPS), and Progeroid Laminopathies are separate and distinct ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients. <\/p>\n<p>Progeria is caused by a point mutation in the LMNA gene, yielding the farnesylated aberrant protein, progerin.\u00a0 Progeroid Laminopathies are genetic conditions of accelerated aging caused by a constellation of mutations in the LMNA and\/or Zmpste24 genes yielding farnesylated proteins that are distinct from progerin.\u00a0 While non\u2013progerin producing, these genetic mutations result in disease manifestations with phenotypes that have overlap with, but are distinct from, Progeria. <\/p>\n<p>Without Zokinvy therapy, children with Progeria commonly die of the same heart disease that affects millions of normally aging adults (arteriosclerosis), by an average age of 14.5 years.\u00a0 Disease manifestations include severe failure to thrive, scleroderma\u2013like skin, global lipodystrophy, alopecia, joint contractures, skeletal dysplasia, global accelerated atherosclerosis with cardiovascular decline, and debilitating strokes.\u00a0 It is estimated that there are 400 children worldwide with Progeria and 200 children with Progeroid Laminopathies.\u00a0 Of these patients, approximately 180 children and young adults have been identified by The Progeria Research Foundation, including approximately 20 in the U.S. and 23 in <span class=\"xn-location\">Europe<\/span>. <\/p>\n<p>\n        <b><br \/>\n          <u>INDICATION<\/u><br \/>\n        <\/b>\n      <\/p>\n<p>ZOKINVY is indicated in adult and pediatric patients 12 months of age and older with a body surface area (BSA) of <span class=\"xn-money\">0.39 m<\/span><sup>2<\/sup> and above:<\/p>\n<ul type=\"disc\">\n<li>To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS) <\/li>\n<li>For the treatment of processing-deficient Progeroid Laminopathies with either: <\/li>\n<ul type=\"circle\">\n<li>Heterozygous LMNA mutation with progerin-like protein accumulation <\/li>\n<li>Homozygous or compound heterozygous ZMPSTE24 mutations<\/li>\n<\/ul>\n<\/ul>\n<p>\n        <b>Limitations of Use<\/b>\n      <\/p>\n<p>ZOKINVY is not indicated for use in patients with non-HGPS Progeroid Syndromes or with Progeroid Laminopathies known to be processing-proficient. Based upon its mechanism of action, ZOKINVY would not be expected to be effective in these populations.<\/p>\n<p>\n        <b>Contraindications<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Strong or moderate CYP3A inhibitors or inducers <\/li>\n<li>Midazolam <\/li>\n<li>Lovastatin, simvastatin, and atorvastatin<\/li>\n<\/ul>\n<p>\n        <b><br \/>\n          <u>IMPORTANT SAFETY INFORMATION<\/u><br \/>\n        <\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>The most common adverse reactions are vomiting (90%), diarrhea (81%), infection (78%), nausea (56%), decreased appetite (53%), fatigue (51%), upper respiratory tract infection (51%), abdominal pain (48%), musculoskeletal pain (48%), electrolyte abnormalities (43%), headache (37%), decreased weight (37%), increased aspartate aminotransferase (35%), myelosuppression (35%), cough (33%), decreased blood bicarbonate (33%), hypertension (29%), and increased alanine aminotransferase (27%).<\/li>\n<\/ul>\n<p>\n        <b>Gastrointestinal Adverse Reactions<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Gastrointestinal adverse reactions were the most frequently reported adverse reactions. Of the 57 patients (90%) that experienced vomiting, 30 (53%) patients had mild vomiting, 26 (46%) patients had moderate vomiting, and 1 (2%) patient had severe vomiting. <\/li>\n<li>Of the 35 patients (56%) that experienced nausea, 34 (97%) patients had mild nausea and 1 (3%) patient had moderate nausea. <\/li>\n<li>Of the 51 patients (81%) that experienced diarrhea, the majority of patients (92%) experienced mild or moderate diarrhea; 38 (75%) patients reported mild diarrhea and 9 (18%) patients reported moderate diarrhea. Four (8%) patients reported severe diarrhea. <\/li>\n<li>Loss of fluids and dehydration can be severe, leading to hospitalization. As a result, patients should receive therapy for diarrhea at the earliest signs in order to avoid possible severe complications.<\/li>\n<\/ul>\n<p>\n        <b>Alanine Aminotransferase and Aspartate Aminotransferase Elevations<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Increased alanine aminotransferase was commonly reported (17 [27%] patients). Of the 17 patients with increased alanine aminotransferase, 14 (82%) patients had mild increases, 1 (6%) patient had moderate increases, and 2 (12%) patients had severe increases. <\/li>\n<li>Increased aspartate aminotransferase was also commonly reported (22 [35%] patients). Of the 22 patients with increased aspartate aminotransferase, 21 (95%) patients had mild increases and 1 (5%) patient had a severe increase.<\/li>\n<\/ul>\n<p>\n        <b>Hypertension<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Increases in blood pressure have been documented in patients treated with ZOKINVY. At baseline 22 (35%) patients had either a systolic blood pressure or a diastolic blood pressure or both above the 95th percentile. Over the course of the trials, 18 (29%) patients had hypertension based on systolic blood pressure or diastolic blood pressure measurements above the 95th percentile on 3 or more occasions. Five (8%) patients who were normotensive at baseline had either systolic blood pressure or diastolic blood pressure above the 95th percentile at the end of treatment. <\/li>\n<\/ul>\n<p>\n        <b>Ophthalmic Adverse Reactions<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Lonafarnib caused retinal toxicity in monkeys at 3.7 times the human dose based on plasma drug exposure, but not at 2.1 times the human dose.<\/li>\n<\/ul>\n<p>\n        <b>Laboratory Abnormalities<\/b>\n      <\/p>\n<p>Some patients treated with ZOKINVY developed laboratory abnormalities. These included:<\/p>\n<ul type=\"disc\">\n<li>Electrolyte abnormalities (43%), such as hyperkalemia, hypokalemia, hyponatremia, or hypercalcemia <\/li>\n<li>Myelosuppression (35%), such as reductions in absolute neutrophil count, white blood cell counts, lymphopenia, hemoglobin, or hematocrit <\/li>\n<li>Increased liver enzymes, such as aspartate aminotransferase (35%), or alanine aminotransferase (27%)<\/li>\n<\/ul>\n<p>These laboratory abnormalities often improved while continuing ZOKINVY, but it is not possible to exclude ZOKINVY as a cause of the abnormalities.\u00a0 Periodically monitor electrolytes, complete blood counts, and liver enzymes, and manage abnormalities accordingly.<\/p>\n<p>\n        <b>Nephrotoxicity<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Lonafarnib caused nephrotoxicity in rats at plasma drug exposures approximately equal to that achieved with the human dose. Monitor renal function at regular intervals during ZOKINVY therapy.<\/li>\n<\/ul>\n<p>\n        <b>Retinal Toxicity<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Lonafarnib caused rod-dependent, low-light vision decline in monkeys at plasma drug exposures similar to that achieved with the human dose. Perform ophthalmological evaluation at regular intervals and at the onset of any new visual changes during ZOKINVY therapy.<\/li>\n<\/ul>\n<p>\n        <b>Impaired Fertility<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Lonafarnib caused impaired fertility in female rats at 1.2 times the human dose based on plasma drug exposure. <\/li>\n<li>Lonafarnib caused impaired fertility and testicular toxicity in male rats at 1.5 times the human dose based on plasma drug exposure, and toxicity in the male reproductive tract in monkeys at doses lower than the human dose based on plasma drug exposure.<\/li>\n<\/ul>\n<p>\n        <b>About Eiger <\/b>\n      <\/p>\n<p>Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis.\u00a0 <\/p>\n<p>Eiger is developing two complementary treatments for HDV.\u00a0 Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial.\u00a0 Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.<\/p>\n<p>Zokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies is the Company&#8217;s first FDA approval.\u00a0 A Marketing Authorization Application (MAA) is under review by the\u00a0European Medicines Agency\u00a0(EMA).\u00a0 Outside the\u00a0U.S., Eiger&#8217;s established global Managed Access Program, expected to span greater than 40 countries, ensures all children and young adults with Progeria and Progeroid Laminopathies have access to treatment.<\/p>\n<p>For additional information about Eiger and its clinical programs, please visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045695-1&amp;h=2703314187&amp;u=http%3A%2F%2Fwww.eigerbio.com%2F&amp;a=www.eigerbio.com\" rel=\"nofollow noopener noreferrer\">www.eigerbio.com<\/a>. <\/p>\n<p>\n        <b>Note Regarding Forward-Looking Statements<\/b>\n      <\/p>\n<p>This press release contains &#8220;forward-looking&#8221; statements that involve substantial risks and uncertainties. \u00a0All statements other than statements of historical facts, including statements regarding our future financial condition, timing for and outcomes of clinical results, business strategy and plans and objectives for future operations, are forward-looking statements. These forward-looking statements include terminology such as &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;contemplate,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;could,&#8221; &#8220;potentially&#8221; or the negative of these terms. \u00a0Forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our anticipating significant milestones in 2021, the timing of our ongoing and planned clinical development, including our ability to support the launch of a new product and ship to specialty pharmacies; the sufficiency of our cash, cash equivalents and investments to fund our operations through at least Q4 2023; the expected closing of the sale of our PRV; our development programs for Zokinvy generally; and the potential approval of Zokinvy in jurisdictions outside of the U.S., including the EU; the risks related to the commercialization of Zokinvy, our ability to manufacture sufficient quantities of Zokinvy, and the commercial launch of Zokinvy in the U.S., the market potential for Zokinvy as a treatment for Progeria and processing-deficient Progeroid Laminopathies; our progression and enrollment of our Phase 3 D-LIVR study in HDV; our ability to maintain supply of our commercial and clinical trial materials; our plans to advance Lambda in HDV in the U.S. and EU; our ability to transition into a commercial stage biopharmaceutical company; our ability to finance the continued advancement of our development pipeline products; and the potential for success of any of our product candidates. \u00a0These statements concern product candidates that have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). \u00a0No representation is made as to their safety or effectiveness for the purposes for which they are being investigated. \u00a0Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including additional applicable risks and uncertainties described in the &#8220;Risk Factors&#8221; sections in the Quarterly Report on Form 10-Q for the quarter ended <span class=\"xn-chron\">September 30, 2020<\/span> and Eiger&#8217;s subsequent filings with the SEC. \u00a0The forward-looking statements contained in this press release are based on information currently available to Eiger and speak only as of the date on which they are made. \u00a0Eiger does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.<\/p>\n<p>Investors and Media: <\/p>\n<p>\n        <span class=\"xn-person\">Sri Ryali<\/span><br \/>\n        <br \/>Email: <a target=\"_blank\" href=\"mailto:sryali@eigerbio.com\" rel=\"nofollow noopener noreferrer\">sryali@eigerbio.com<\/a>\u00a0 <br \/>Phone: 1-650-272-6138<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE57372&amp;sd=2021-01-25\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/eiger-biopharmaceuticals-announces-us-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies-301213799.html\">http:\/\/www.prnewswire.com\/news-releases\/eiger-biopharmaceuticals-announces-us-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies-301213799.html<\/a><\/p>\n<p>SOURCE  Eiger BioPharmaceuticals, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE57372&amp;Transmission_Id=202101250800PR_NEWS_USPR_____NE57372&amp;DateId=20210125\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; The Eiger OneCare\u2122 Program Provides Ongoing Patient Support Services PR Newswire PALO ALTO, Calif., Jan. 25, 2021 \/PRNewswire\/ &#8212;\u00a0Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced the commercial launch and availability of Zokinvy\u2122\u00a0(lonafarnib) in the United States. \u00a0Zokinvy was approved by the U.S. Food and Drug Administration (FDA) in November 2020 to reduce the risk of death in patients with Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and for the treatment of processing-deficient progeroid laminopathies. &#8220;Eiger sought regulatory approval of Zokinvy to ensure continued access to the only drug proven to reduce the risk of death in patients with Progeria,&#8221; said Eldon Mayer, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy\u2122 (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-420153","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy\u2122 (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy\u2122 (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; The Eiger OneCare\u2122 Program Provides Ongoing Patient Support Services PR Newswire PALO ALTO, Calif., Jan. 25, 2021 \/PRNewswire\/ &#8212;\u00a0Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced the commercial launch and availability of Zokinvy\u2122\u00a0(lonafarnib) in the United States. \u00a0Zokinvy was approved by the U.S. Food and Drug Administration (FDA) in November 2020 to reduce the risk of death in patients with Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and for the treatment of processing-deficient progeroid laminopathies. &#8220;Eiger sought regulatory approval of Zokinvy to ensure continued access to the only drug proven to reduce the risk of death in patients with Progeria,&#8221; said Eldon Mayer, &hellip; Continue reading &quot;Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy\u2122 (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-25T13:03:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy\u2122 (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies\",\"datePublished\":\"2021-01-25T13:03:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\\\/\"},\"wordCount\":1798,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/285009\\\/eiger_biopharmaceuticals_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\\\/\",\"name\":\"Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy\u2122 (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/285009\\\/eiger_biopharmaceuticals_logo.jpg\",\"datePublished\":\"2021-01-25T13:03:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/285009\\\/eiger_biopharmaceuticals_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/285009\\\/eiger_biopharmaceuticals_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy\u2122 (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy\u2122 (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/","og_locale":"en_US","og_type":"article","og_title":"Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy\u2122 (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies - Market Newsdesk","og_description":"&#8211; The Eiger OneCare\u2122 Program Provides Ongoing Patient Support Services PR Newswire PALO ALTO, Calif., Jan. 25, 2021 \/PRNewswire\/ &#8212;\u00a0Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced the commercial launch and availability of Zokinvy\u2122\u00a0(lonafarnib) in the United States. \u00a0Zokinvy was approved by the U.S. Food and Drug Administration (FDA) in November 2020 to reduce the risk of death in patients with Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and for the treatment of processing-deficient progeroid laminopathies. &#8220;Eiger sought regulatory approval of Zokinvy to ensure continued access to the only drug proven to reduce the risk of death in patients with Progeria,&#8221; said Eldon Mayer, &hellip; Continue reading \"Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy\u2122 (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-25T13:03:45+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy\u2122 (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies","datePublished":"2021-01-25T13:03:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/"},"wordCount":1798,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/","name":"Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy\u2122 (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg","datePublished":"2021-01-25T13:03:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/285009\/eiger_biopharmaceuticals_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eiger-biopharmaceuticals-announces-u-s-commercial-availability-of-zokinvy-lonafarnib-the-first-and-only-treatment-approved-for-progeria-and-processing-deficient-progeroid-laminopathies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy\u2122 (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/420153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=420153"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/420153\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=420153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=420153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=420153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}